RCRuohua Chen

Ruohua Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruohua Chen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MRI-based Ovarian Lesion Classification via a Foundation Segmentation Model and Multimodal Analysis: A Multicenter Study

    by Wen-Chi Hsu, Yuli Wang, Yu-Fu Wu, Ruohua Chen, Shadi Afyouni, Jhehong Liu, Somasundaram Vin, Victoria Shi, Maliha Imami, Jill S. Chotiyanonta, et al.

    Combining the Segment Anything Model with a deep learning classifier produced an efficient pipeline for classifying MRI ovarian lesions, improving segmentation speed and matching radiologists’ classification performance.


  • Multistage Diffusion Model With Phase Error Correction for Fast PET Imaging

    by Yunlong Gao, Zhenxing Huang, Xingyu Xie, Wenjie Zhao, Qianyi Yang, Xinlan Yang, Yongfeng Yang, Hairong Zheng, Dong Liang, Jianjun Liu, et al.

    Fast PET imaging is clinically important for reducing motion artifacts and improving patient comfort. While recent diffusion-based deep learning methods have shown promise, they often fail to capture the true PET degradation process, suffer from accumulated inference errors, introduce artifacts, and require extensive reconstruction iterations. To address these challenges, we propose a novel multistage diffusion framework tailored for fast PET imaging. At the coarse level, we design a multistage structure to approximate the temporal non-linear PET degradation process in a data-driven manner, using paired PET images collected under different acquisition duration. A Phase Error Correction Network (PECNet) ensures consistency across stages by correcting accumulated deviations. At the fine level, we introduce a deterministic cold diffusion mechanism, which simulates intra-stage degradation through interpolation between known acquisition durations—significantly reducing reconstruction iterations to as few as 10. Evaluations on [68Ga]FAPI and [18F]FDG PET datasets demonstrate the superiority of our approach, achieving peak PSNRs of 36.2 dB and 39.0 dB, respectively, with average SSIMs over 0.97. Our framework offers high-fidelity PET imaging with fewer iterations, making it practical for accelerated clinical imaging.


  • Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [68Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs

    by Ruohua Chen, Yee Ling Ng, Xinlan Yang, Yinjie Zhu, Lianghua Li, Haitao Zhao, Gang Huang, Jianjun Liu

    Purpose This study aimed to quantitatively assess [68Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs in prostate cancer using the total-body [68Ga]Ga-PSMA-11 PET/CT and to characterize the dynamic metabolic heterogeneity of prostate cancer. Methods Dynamic total-body [68Ga]Ga-PSMA-11 PET/CT scans were performed on ten prostate cancer patients. Manual delineation of volume-of-interests (VOIs) was performed on multiple normal organs displaying high [68Ga]Ga-PSMA-11 uptake, as well as pathological lesions. Time-to-activity curves (TACs) were generated, and the four compartment models including one-tissue compartmental model (1T1k), reversible one-tissue compartmental model (1T2k), irreversible two-tissue compartment model (2T3k) and reversible two-tissue compartmental model (2T4k) were fitted to each tissue TAC. Various rate constants, including K1 (forward transport rate from plasma to the reversible compartment), k2 (reverse transport rate from the reversible compartment to plasma), k3 (tracer binding on the PSMA-receptor and its internalization), k4 (the externalization rate of the tracer) and Ki (net influx rate), were obtained. The selection of the optimal model for describing the uptake of both lesions and normal organs was determined using the Akaike information criteria (AIC). Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off values for differentiating physiological and pathological [68Ga]Ga-PSMA-11 uptake. Results Both 1T1k and 1T2k models showed relatively high AIC values compared to the 2T3k and 2T4k models in both pathological lesions and normal organs. The kinetic behavior of pathological lesions was better described by the 2T3k model compared to the 2T4k model, while the normal organs were better described by the 2T4k model. Significant variations in kinetic metrics, such as K1, k2, and k3, and Ki, were observed among normal organs with high [68Ga]Ga-PSMA-11 uptake and pathological lesions. The high Ki value in normal organs was primarily determined by elevated K1 and low k3, rather than k2. Conversely, the high Ki value in pathological lesions, ranking second to the kidney and similar to salivary glands and spleen, was predominantly determined by the highest k3 value. Notably, k3 exhibited the highest performance in distinguishing between physiological and pathological [68Ga]Ga-PSMA-11 uptake, with an area under the curve (AUC) of 0.844 (95% CI, 0.773–0.915), sensitivity of 82.9%, and specificity of 74.1%. The k3 values showed better performance than SUVmean (AUC, 0.659), SUVmax (AUC, 0.637), and other kinetic parameter including K1 (AUC, 0.604), k2 (AUC, 0.634), and Ki (AUC, 0.651). Conclusions Significant discrepancies in kinetic metrics were detected between pathological lesions and normal organs, despite their shared high uptake of [68Ga]Ga-PSMA-11. Notably, the k3 value exhibits a noteworthy capability to distinguish between pathological lesions and normal organs with elevated [68Ga]Ga-PSMA-11 uptake. This discovery implies that k3 holds promise as a prospective imaging biomarker for distinguishing between pathologic and non-specific [68Ga]Ga-PSMA-11 uptake in patients with prostate cancer.


  • Open Access

    Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

    by Yiping Shi, Lian Xu, Yinjie Zhu, Yining Wang, Ruohua Chen, Jianjun Liu

    Purpose: Differentiating lymph node metastases (LNM) from peripheral ganglia by physiological prostate-specific membrane antigen (PSMA) uptake is challenging. Two tracers (68Ga-PSMA-11 and 18F-fluorodeoxyglucose [FDG]) metabolic uptake patterns were evaluated by positron emission tomography-computed tomography (PET-CT), searching for differences that could tell ganglia from LNM.Methods: Dual 68Ga-PSMA-11 and 18F-FDG PET-CT data of 138 prostate cancer patients acquired from June 2018 to December 2019 were retrospectively evaluated. Ganglia and LNM with PSMA-11 uptake above local background were analyzed by the location and PSMA-11-PET and FDG-PET maximum standardized uptake value (SUVmax).Results: PSMA-11-positive ganglia (n = 381) and LNM (n = 83) were identified in 138 and 58 patients, respectively. The LNM SUVmax of PSMA-11-PET (16.4 ± 14.8 vs 2.3 ± 0.7, P < 0.001) and FDG-PET (3.3 ± 3.2 vs 1.5 ± 0.5, P < 0.001) were higher than in ganglia. The probabilities of being an LNM in the low-potential (PSMA-11-PET SUVmax of 4.1 and FDG-PET SUVmax of >2.05) groups were 0.9% (3/334), 44.6% (37/83), and 91.5% (43/47), respectively (P < 0.001). The cervical and coeliac ganglia had higher PSMA-11 and FDG uptake than the sacral ganglia (P < 0.001 for all). LNM PSMA-11 and FDG uptake was similar in these three locations.Conclusion: The FDG-PET and PSMA-11-PET SUVmax, especially when combined, could well differentiate LNM from ganglia. The tracers uptake differed between cervical/coeliac and sacral ganglia, so the lesion location should be considered during image assessment.